Sargramostim/GM-CSF holds promise as an AD therapeutic due to its ability to increase microglial proliferation and boost microglial activity and cytokine production in such a way that demonstrates positive cognitive effects (Jim et al., 2012; Potter et al., 2021). The gene discussed is CSF2; the disease is Alzheimer disease.